Myriad Genetics hosted an Investor Day on Aug. 11, 2022, providing a strategic business update and overview of the company’s growth opportunities, research and development pipeline, and technology initiatives to expand its reach and make it easier for healthcare providers and their patients to benefit from genetic insights.
Results from a nationwide survey conducted on the attitudes, knowledge, and practices related to risk assessment, prevention, and screening for breast and ovari...
Revenue of $179.3 million for the quarter ended June 30, 2022
Excluding revenue from divested businesses, revenue increased 7% year-over-year an...
Myriad Genetics, Inc., (NASDAQ: MYGN), will host an Investor Day on Aug. 11, 2022, providing a strategic business update and overview of the company’s growth ...
“For more than 31 years, Myriad Genetics has worked to be a force for good in the world as we fulfill our mission to advance health and well-being for all. In our inaugural ESG report, we seek to convey our core values as a caring, ethical, and sustainable company committed to continuous improvement,” said Paul J. Diaz, president and CEO, Myriad Genetics. “I want to thank our 2,400 teammates for the progress we have made to date, recognizing we have more work to be done. We are committed to intensifying our ESG focus helping to address the needs of the patients, healthcare providers, stakeholders, and communities we serve.”